vs
Side-by-side financial comparison of CareTrust REIT, Inc. (CTRE) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
Stoke Therapeutics, Inc. is the larger business by last-quarter revenue ($158.6M vs $134.9M, roughly 1.2× CareTrust REIT, Inc.). CareTrust REIT, Inc. runs the higher net margin — 82.5% vs 71.2%, a 11.3% gap on every dollar of revenue. On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs 55.1%).
CareTrust REIT, Inc.CTREEarnings & Financial Report
Target Healthcare REIT is a British property investment company which invests in healthcare properties and holds a large portfolio of care homes. It is structured as a real estate investment trust (REIT) and is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
CTRE vs STOK — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | ||
|---|---|---|
| Revenue | $134.9M | $158.6M |
| Net Profit | $111.3M | $112.9M |
| Gross Margin | — | — |
| Operating Margin | — | 70.2% |
| Net Margin | 82.5% | 71.2% |
| Revenue YoY | 55.1% | 3661.1% |
| Net Profit YoY | 113.5% | 528.0% |
| EPS (diluted) | $0.52 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $134.9M | — | ||
| Q3 25 | $132.4M | — | ||
| Q2 25 | $112.5M | — | ||
| Q1 25 | $96.6M | $158.6M | ||
| Q4 24 | $86.9M | $22.6M | ||
| Q3 24 | $77.4M | — | ||
| Q2 24 | $68.9M | — | ||
| Q1 24 | $63.1M | — |
| Q4 25 | $111.3M | — | ||
| Q3 25 | $74.9M | — | ||
| Q2 25 | $68.5M | — | ||
| Q1 25 | $65.8M | $112.9M | ||
| Q4 24 | $52.1M | $-10.5M | ||
| Q3 24 | $33.4M | — | ||
| Q2 24 | $10.8M | — | ||
| Q1 24 | $28.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | 58.1% | — | ||
| Q2 25 | 61.3% | — | ||
| Q1 25 | — | 70.2% | ||
| Q4 24 | — | -60.4% | ||
| Q3 24 | 43.0% | — | ||
| Q2 24 | 15.1% | — | ||
| Q1 24 | — | — |
| Q4 25 | 82.5% | — | ||
| Q3 25 | 56.6% | — | ||
| Q2 25 | 60.9% | — | ||
| Q1 25 | 68.1% | 71.2% | ||
| Q4 24 | 60.0% | -46.4% | ||
| Q3 24 | 43.2% | — | ||
| Q2 24 | 15.6% | — | ||
| Q1 24 | 45.6% | — |
| Q4 25 | $0.52 | — | ||
| Q3 25 | $0.35 | — | ||
| Q2 25 | $0.35 | — | ||
| Q1 25 | $0.35 | $1.90 | ||
| Q4 24 | $0.30 | $-0.15 | ||
| Q3 24 | $0.21 | — | ||
| Q2 24 | $0.07 | — | ||
| Q1 24 | $0.22 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | ||
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $198.0M | $274.8M |
| Total DebtLower is stronger | $894.2M | — |
| Stockholders' EquityBook value | $4.0B | $350.1M |
| Total Assets | $5.1B | $406.9M |
| Debt / EquityLower = less leverage | 0.22× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $198.0M | — | ||
| Q3 25 | $712.5M | — | ||
| Q2 25 | $306.1M | — | ||
| Q1 25 | $26.5M | $274.8M | ||
| Q4 24 | $213.8M | $128.0M | ||
| Q3 24 | $377.1M | — | ||
| Q2 24 | $495.1M | — | ||
| Q1 24 | $451.2M | — |
| Q4 25 | $894.2M | — | ||
| Q3 25 | $893.8M | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $822.1M | — | ||
| Q4 24 | $396.9M | — | ||
| Q3 24 | $396.7M | — | ||
| Q2 24 | $671.1M | — | ||
| Q1 24 | $595.9M | — |
| Q4 25 | $4.0B | — | ||
| Q3 25 | $4.0B | — | ||
| Q2 25 | $3.3B | — | ||
| Q1 25 | $2.9B | $350.1M | ||
| Q4 24 | $2.9B | $229.0M | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $1.9B | — | ||
| Q1 24 | $1.7B | — |
| Q4 25 | $5.1B | — | ||
| Q3 25 | $5.1B | — | ||
| Q2 25 | $4.7B | — | ||
| Q1 25 | $3.9B | $406.9M | ||
| Q4 24 | $3.4B | $271.6M | ||
| Q3 24 | $2.9B | — | ||
| Q2 24 | $2.7B | — | ||
| Q1 24 | $2.3B | — |
| Q4 25 | 0.22× | — | ||
| Q3 25 | 0.22× | — | ||
| Q2 25 | 0.35× | — | ||
| Q1 25 | 0.28× | — | ||
| Q4 24 | 0.14× | — | ||
| Q3 24 | 0.16× | — | ||
| Q2 24 | 0.35× | — | ||
| Q1 24 | 0.36× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | ||
|---|---|---|
| Operating Cash FlowLast quarter | $394.0M | $131.8M |
| Free Cash FlowOCF − Capex | — | $131.7M |
| FCF MarginFCF / Revenue | — | 83.0% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | 3.54× | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $394.0M | — | ||
| Q3 25 | $100.9M | — | ||
| Q2 25 | $100.8M | — | ||
| Q1 25 | $71.4M | $131.8M | ||
| Q4 24 | $244.3M | $-23.2M | ||
| Q3 24 | $67.2M | — | ||
| Q2 24 | $53.0M | — | ||
| Q1 24 | $48.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $131.7M | ||
| Q4 24 | — | $-23.2M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 83.0% | ||
| Q4 24 | — | -102.7% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 3.54× | — | ||
| Q3 25 | 1.35× | — | ||
| Q2 25 | 1.47× | — | ||
| Q1 25 | 1.08× | 1.17× | ||
| Q4 24 | 4.68× | — | ||
| Q3 24 | 2.01× | — | ||
| Q2 24 | 4.92× | — | ||
| Q1 24 | 1.70× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.